SEVICONTROL-2: Efficacy and Safety of a sequential therapy change from Candesartan 32 mg to the fixed combination of olmesartan 40 mg/amlodipine 10 mg in patients with poorly controlled moderate hypertension - an open phase IV trial.

Trial Profile

SEVICONTROL-2: Efficacy and Safety of a sequential therapy change from Candesartan 32 mg to the fixed combination of olmesartan 40 mg/amlodipine 10 mg in patients with poorly controlled moderate hypertension - an open phase IV trial.

Completed
Phase of Trial: Phase IV

Latest Information Update: 30 Jun 2017

At a glance

  • Drugs Olmesartan medoxomil/amlodipine (Primary) ; Candesartan cilexetil
  • Indications Essential hypertension
  • Focus Therapeutic Use
  • Acronyms SEVICONTROL-2
  • Most Recent Events

    • 13 Dec 2012 Status changed from recruiting to completed as reported by European Clinical Trials Database record.
    • 01 Jun 2012 Additional lead trial investigators identified as reported by ClinicalTrials.gov.
    • 01 Jun 2012 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health: NCT01611077).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top